“…After discarding those which clearly did not meet the criteria, 19 studies were further assessed for eligibility (Piyathilake et al, 2000;Goodman et al, 2001;Gerhard et al, 2003;Lambropoulos et al, 2003;Sull et al, 2004;Kang et al, 2005;Zoodsma et al, 2005;Delgado-Enciso et al, 2006;Rao et al, 2006;Piyathilake et al, 2007;Nandan et al, 2008;Shekari et al, 2008;Agodi et al, 2010;Kohaar et al, 2010;Tong et al, 2010;Mostowska et al, 2011;Prasad and Wilkhoo, 2011;Tong et al, 2011;von Keyserling et al, 2011). After reviewing each original paper and extracting data, nine studies were excluded including five studies focusing on cervical intraepithelial neoplasia (Piyathilake et al, 2000;Goodman et al, 2001;Lambropoulos et al, 2003;Piyathilake et al, 2007;Agodi et al, 2010), three studies for not specifying genotypic frequencies of CC, CT, and TT (Gerhard et al, 2003;Nandan et al, 2008;Rao et al, 2006) and one study for overlapping data (Tong et al, 2010). Finally, 10 casecontrol studies with a total of 2113 cervical cancer cases and 2804 controls were included into this meta-analysis (Sull et al, 2004;Kang et al, 2005;Zoodsma et al, 2005;Delgado-Enciso et al, 2006;Shekari et al, 2008;Kohaar et al, 2010;Mostowska et al, 2011;...…”